Business
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing for
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n\nRecently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors\n\n\n\nEnrollment ongoing for JANX007 and JANX008\n\n\n\nUpdate on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024\n\n\n\n$344.0 million in year-end cash, cash equivalents, and short-term investments\n\n\n\nIn March, further strengthened balance sheet with approximately $320.2 million net proceeds from underwritten offering\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.\n\n\n“2023 was a critical year for Janux as we tested the potential power of our TRACTr platform in the clinic. We believe the data recently presented from both of our clinical programs displays the profound impact we can have on patients through our tumor-activated approach. We are excited to be helping cancer patients who need novel therapies and with our substantial cash runway we feel well-positioned to execute on our clinical plan,” said David Campbell, Ph.D., President and CEO of Janux.\n\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\n\n\nPresented positive updated interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer in February 2024. As of February 12, 2024:\n\n\nIncreasing depth of PSA declines and RECIST responses at higher doses were observed, while a favorable safety profile was maintained.\n\n\n\n83% (5/6) of subjects achieved PSA50 declines with first step dose ≥ 0.2mg.\n\n\n\n56% (10/18) of subjects achieved PSA50 declines with first dose ≥ 0.1mg.\n\n\n\nNo CRS > Grade 2 observed in heavily pre-treated late stage mCRPC population.\n\n\n\nMajority of non-CRS treatment-related adverse events (TRAEs) were Grade 1 or 2.\n\n\n\nLow incidence of Grade 3 TRAEs, and no Grade 4 or 5 events were observed.\n\n\n\nJANX007 has been administered at doses up to 3mg, significantly exceeding the anticipated maximum tolerable dose for the parental T cell engager, while ...